Compare Taskus Inc (TASK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Taskus Inc vs TG Therapeutics Inc — how do they compare? Taskus Inc trades at $6.91 (market cap $650.52M), while TG Therapeutics Inc trades at $49.94 (market cap $7.53B). The key difference: TG Therapeutics Inc is far larger — about 11.6× Taskus Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals.
| TASK | TGTX | |
|---|---|---|
Market Cap | $650.52M | $7.53B |
Sector | Technology | Health |
52-Week High | $18.21 | $59.06 |
52-Week Low | $4.57 | $26.39 |
Enterprise Value | $1.02B | $7.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TaskUs (TASK) trades at $7.30, down 6.65% today, but maintains strong fundamentals with Q2 2026 revenue beating guidance by $10.9 million. The stock shows bullish technical signals with support at $7 and bullish moving averages. Valuation metrics appear attractive with P/E of 6.29 and P/S of 0.55, while profitability remains solid with 8.75% net margin and 25.43% ROE. Recent CFO appointment and AI services growth provide positive catalysts.
The outlook remains positive with analyst consensus favoring Buy ratings (54.55%) and improving cash flow trends. Key opportunities include undervaluation relative to earnings power and AI services expansion. Risks include client concentration and potential earnings volatility. The combination of reasonable valuation and growth momentum supports a constructive view for patient investors.
TG Therapeutics (TGTX) trades at $49.76, up 0.42% in the last session, with a bearish technical signal from moving averages. Recent earnings missed estimates, but revenue growth is strong, driven by BRIUMVI sales, with 2026 guidance raised to $950 million. The stock faces near-term pressure from earnings underperformance and a legal investigation into potential fiduciary breaches.
The outlook is mixed: strong revenue momentum and a high analyst buy rating (84.62%) support upside to the $63.75 consensus target, but risks include earnings volatility, high valuation multiples, and legal overhangs. Investors should weigh robust growth prospects against execution and sentiment challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
